Cytidine-5?-diphosphocholine (Citicoline): a pilot study in patients with non-arteritic ischaemic optic neuropathy.
V. Parisi,G. Coppola, L. Ziccardi, G. Gallinaro, B. Falsini. European Journal of Neurology. Volume 15, Issue 5, pages 465?474, May 2008
Twenty-six patients in which at least 6 months elapsed from NION, were randomly divided into two age-similar groups: 14 patients had Citicoline (Cebrolux-Tubilux, Italy, 1600 mg/diem for 60 days, followed by a 120-day period of wash out, days 60?180) (T-NION); 12 patients had no treatment
during the same period (NT-NION). At day 180, in T-NION a second period of treatment (days 181?240) followed by a wash-out (days 241?360) was performed. Fourteen age-matched healthy subjects provided normative data. In all patients, pattern-electroretinogram (PERG), visual evoked potentials (VEPs) and visual acuity (VA) measurements were performed at baseline and at days 60 and 180. In T-NION, further measurements were achieved at days 240 and 360.